Nanobiotix ( (NBTX) ) has provided an update.
On April 14, 2025, Nanobiotix announced an update on its voting rights and share capital, revealing a total of 47,426,851 shares outstanding as of March 31, 2025. The announcement, which aligns with French regulatory requirements, provides transparency to stakeholders about the company’s voting rights structure, potentially impacting investor decisions and market perceptions.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Underperform.
Nanobiotix’s overall stock score reflects significant financial difficulties, including negative revenue and high leverage. Technical indicators suggest weak momentum, and the stock appears overvalued relative to its earnings. The strategic partnership with JNJ offers potential future benefits but does not offset the current financial challenges. Investors should approach with caution due to the high risk associated with the company’s financial instability.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company based in Paris, France, specializing in innovative, physics-based therapeutic solutions aimed at improving treatment outcomes for patients. Founded in 2003, the company is publicly traded on Euronext Paris and the Nasdaq Global Select Market. It holds over 25 patent families across three nanotechnology platforms with applications in oncology, bioavailability and biodistribution, and central nervous system disorders.
YTD Price Performance: 14.90%
Average Trading Volume: 11,140
Technical Sentiment Signal: Buy
Current Market Cap: $158.3M
Learn more about NBTX stock on TipRanks’ Stock Analysis page.